Novartis Cosentyx shows encouraging results versus Humira * from first-of-its-kind head-to-head trial in psoriatic arthritis

  • Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira *
     
  • Statistically significant advantages of Cosentyx versus Humira * in psoriatic arthritis (PsA)-specific endpoints were observed in a pre-specified sensitivity analysis
     
  • EXCEED underscores Novartis commitment in rheumatology as first double-blinded monotherapy head-to-head trial with a primary endpoint specific to joints in PsA  

Basel, November 1, 2019 - Novartis, a leader in rheumatology and immuno-dermatology, today announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira * (adalimumab) in patients with active psoriatic arthritis (PsA) . While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira * . Statistically significant advantages of Cosentyx versus Humira * in PsA-specific endpoints were observed in a pre-specified sensitivity analysis. The trial demonstrated a consistent and favorable safety profile for Cosentyx in line with previous clinical trials , - . No new safety signals were detected.

"These data will be welcomed by patients and clinicians to guide clinical decision making and highlight secukinumab as a viable option as a first-line biologic for the treatment of psoriatic arthritis," said Iain McInnes, Professor of Rheumatology, University of Glasgow and an investigator in the secukinumab clinical trial program.

"EXCEED is the first ever monotherapy head-to-head trial with a primary endpoint in psoriatic arthritis specific to joints." said Eric Hughes, Global Development Unit Head, Immunology, Hepatology & Dermatology. "Novartis continues to reimagine care for patients and advance science in rheumatology. We will assess the EXCEED data in their totality and we view the results as confirming our vision of Cosentyx becoming standard of care in psoriatic arthritis."

Detailed data is planned to be presented at a future scientific congress.

Cosentyx is the only biologic with proven efficacy in all key manifestations of psoriatic arthritis  and is backed by 5-year sustained efficacy and consistent safety data across psoriatic arthritis, ankylosing spondylitis and psoriasis - . To date, over 250,000 patients have been treated worldwide.

About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex disease with multiple manifestations driving patient symptoms , . It is estimated to affect up to 50 million people worldwide , .

PsA is part of a family of life-long inflammatory diseases (spondyloarthritis) that target the joints and is closely associated with psoriasis. Approximately 40% of patients with psoriasis have PsA  and as many as one in four people with psoriasis may have undiagnosed PsA. Symptoms of PsA include joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful swelling of the tendons, and irreversible joint damage.

About EXCEED
EXCEED is the first double-blinded head-to-head clinical trial evaluating Cosentyx (secukinumab) 300 mg versus Humira * (adalimumab) 40 mg. EXCEED is a 52-week, multi-center, randomized, double-blind, active control, Phase IIIb trial evaluating the efficacy of Cosentyx compared with Humira * in patients with active PsA who are naļve to biologic therapy. The trial involves over 800 biologic-naļve patients with PsA.

The primary endpoint assessed statistical superiority of Cosentyx monotherapy against Humira * monotherapy for ACR20 response rates at Week 52. The ACR20 is a composite measure defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, Health Assessment Questionnaire (HAQ), visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP). Key secondary endpoints, tested for superiority at Week 52, are PASI90, ACR50, physical function (HAQ-DI (disability index) score relative to baseline), and resolution of enthesitis. PASI stands for Psoriasis Area and Severity Index.

Cosentyx 300 mg was administered at baseline, weeks 1-4, and then every 4 weeks until Week 48. Humira * 40 mg was administered at baseline, and then every 2 weeks until Week 50.


This site uses cookies and analysis tools to improve the usability of the site. More information. |